Literature DB >> 9563483

Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps.

A K Batta1, G Salen, H Holubec, T A Brasitus, D Alberts, D L Earnest.   

Abstract

We recently showed that feeding the cytoprotective bile acid ursodeoxycholic acid (UDCA) to rats resulted in significant reduction in polyps and especially cancers, both in number and size (D. L. Earnest et al., Cancer Res., 54: 5071-5074, 1994). Because fecal secondary bile acids [particularly deoxycholic acid (DCA)] are considered to promote formation of colon adenomas and cancer, we have now attempted to find a relationship between polyp reduction and fecal secondary bile acids after feeding UDCA to these rats. We examined the fecal bile acids in rats with polyps and compared them with fecal bile acids in control rats and also determined the bile acid composition in fecal aqueous phase, which is in direct contact with the colon epithelium and may be physiologically more active. Treatment with azoxymethane did not significantly alter fecal bile acid composition in the rats. Cholic acid feeding resulted in greatly increased proportions of DCA (82% of total bile acids versus 18% in control rats). On the other hand, UDCA feeding significantly reduced the proportion of fecal DCA (2% in control rats fed UDCA and 3% in rats also treated with azoxymethane). In control rats, 96% of the bile acids were present in the water-insoluble fraction and 4% in the water-soluble fraction. The major insoluble bile acids included DCA and hyodeoxycholic acid (73% of total bile acids). In contrast, the muricholic acids were concentrated in the soluble fraction (37%). When 0.4% UDCA was added to the diet, lithocholic acid increased in the insoluble fraction (40 versus 1%), but the hydrophilic UDCA and muricholic acids were enriched in the water-soluble fraction (37 and 43%, respectively). Thus, the hydrophobic bile acids were distributed predominantly in the water-insoluble fraction, whereas the hydrophilic bile acids were distributed preferentially in the water-soluble fraction. These data suggest that UDCA may prevent colon tumors and polyps by countering the toxic effect of DCA and enhancing the possible cytoprotective effects of UDCA and muricholic acids in the water-soluble fraction in the feces of rat.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563483

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.

Authors:  Rosy Wang; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

2.  Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon.

Authors:  Noa Krugliak Cleveland; David T Rubin; John Hart; Christopher R Weber; Katherine Meckel; Anthony L Tran; Arthur S Aelvoet; Isabella Pan; Alex Gonsalves; John Nick Gaetano; Kelli M Williams; Kristen Wroblewski; Bana Jabri; Joel Pekow
Journal:  Clin Gastroenterol Hepatol       Date:  2017-07-26       Impact factor: 11.382

Review 3.  Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Christos Tsaitas; Anysia Semertzidou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2014-04-27

4.  High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.

Authors:  John E Eaton; Marina G Silveira; Darrell S Pardi; Emmanouil Sinakos; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2011-05-10       Impact factor: 10.864

5.  Physical activity as a determinant of fecal bile acid levels.

Authors:  Betsy C Wertheim; María Elena Martínez; Erin L Ashbeck; Denise J Roe; Elizabeth T Jacobs; David S Alberts; Patricia A Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

Review 6.  A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Authors:  Elizabeth C Goode; Simon M Rushbrook
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

7.  Diversity of Intestinal Clostridium coccoides Group in the Japanese Population, as Demonstrated by Reverse Transcription-Quantitative PCR.

Authors:  Takashi Kurakawa; Kiyohito Ogata; Kazunori Matsuda; Hirokazu Tsuji; Hiroyuki Kubota; Toshihiko Takada; Yukiko Kado; Takashi Asahara; Takuya Takahashi; Koji Nomoto
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

8.  The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study.

Authors:  Wen-Kuan Huang; Hung-Chih Hsu; Jia-Rou Liu; Tsai-Sheng Yang; Jen-Shi Chen; John Wen-Cheng Chang; Yung-Chang Lin; Kuang-Hui Yu; Chang-Fu Kuo; Lai-Chu See
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 9.  Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.

Authors:  Carolina Palmela; Farhad Peerani; Daniel Castaneda; Joana Torres; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

10.  Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats.

Authors:  Tomio Narisawa; Yoko Fukaura; Naomi Takeba; Keiko Nakai
Journal:  Jpn J Cancer Res       Date:  2002-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.